Guy MacDonald
Presidente en SCYNEXIS, INC. .
Fortuna: 32 340 $ al 30/04/2024
Perfil
Guy MacDonald is currently the Chairman at SCYNEXIS, Inc. He previously served as Chairman at F-Star Therapeutics, Inc. and as Director at Tetraphase Pharmaceuticals, Inc. He also held the position of Vice President-Anti Infective & Hospital Products at Merck & Co., Inc. and Executive Vice President-Operations at Idenix Pharmaceuticals LLC.
Mr. MacDonald completed his undergraduate degree at the University Of Dundee.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
SCYNEXIS, INC.
0.06% | 31/03/2024 | 22 000 ( 0.06% ) | 32 340 $ | 30/04/2024 |
Cargos activos de Guy MacDonald
Empresas | Cargo | Inicio |
---|---|---|
SCYNEXIS, INC. | Presidente | 04/06/2015 |
Antiguos cargos conocidos de Guy MacDonald.
Empresas | Cargo | Fin |
---|---|---|
TETRAPHASE PHARMACEUTICALS, INC. | Director Ejecutivo | 01/08/2019 |
SPRING BANK PHARMACEUTICALS, INC. | Presidente | 17/08/2015 |
IDENIX PHARMACEUTICALS INC | Director de Operaciones | 01/01/2008 |
MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2003 |
Formación de Guy MacDonald.
University Of Dundee | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
MERCK & CO., INC. | Health Technology |
SCYNEXIS, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Idenix Pharmaceuticals LLC
Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
F-Star Therapeutics, Inc. (United States)
F-Star Therapeutics, Inc. (United States) Pharmaceuticals: MajorHealth Technology F-Star Therapeutics, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Guy MacDonald